Compare Amgen, Inc. (AMGN) vs VanEck Video Gaming and eSports ETF (ESPO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs VanEck Video Gaming and eSports ETF — how do they compare? Amgen, Inc. trades at $357.49 (market cap $196.12B), while VanEck Video Gaming and eSports ETF trades at $91.73. The key difference: Amgen, Inc. pays a 2.77% dividend while VanEck Video Gaming and eSports ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, VanEck Video Gaming and eSports ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | ESPO | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Sector/Thematic |
52-Week High | $388.16 | $122.30 |
52-Week Low | $271.18 | $85.25 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
ESPO trades at $92.35, down 0.52% on the day, with a bullish technical signal driven by moving averages. The ETF's focus on video gaming and esports capitalizes on digital entertainment growth, supported by institutional accumulation. Key resistance lies near $93, with RSI levels indicating potential overbought conditions.
Outlook remains positive due to AI-driven profit potential in gaming, though high RSI suggests near-term consolidation risk. Investors benefit from exposure to a high-growth sector, but should monitor valuation metrics as financial ratios are currently undisclosed.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About VanEck Video Gaming and eSports ETF
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →
